Oxecta oxycodone regulatory update

FDA approved an NDA from Pfizer's King Pharmaceuticals Inc. subsidiary for Oxecta oxycodone to manage acute and chronic moderate to severe pain where the use of an opioid analgesic is appropriate. The approval triggers a $20 million milestone payment to Acura from Pfizer, which gained exclusive rights to the oral immediate-release oxycodone tablet utilizing Acura's Aversion abuse-deterrent technology through its acquisition of King. Pfizer expects to launch the product next half, but has not determined pricing. ...